Imaging Agent Able to Detect Early and Advanced Prostate Cancers by Tracking Biomarkers

Imaging Agent Able to Detect Early and Advanced Prostate Cancers by Tracking Biomarkers
A new imaging agent may hold promise in detecting both early prostate cancer and metastasis using PET/CT scans, according to data from a first-in-human trial. The agent, a radiolabeled dual-receptor, was shown to effectively track cancer cells, and have the potential to improve prostate cancer diagnosis and guide treatment decisions. The study, “Clinical Translation Of A Dual Integrin α3 And GRPR Targeting PET Radiotracer 68Ga-BBN-RGD,” was published in the Journal of Nuclear Medicine. "Although treatable at the early stage, prostate cancer is prone to metastasis," Xiaoyuan Chen, the study's senior author, said in a
Subscribe or to access all post and page content.